PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Mills, Anthony
TI  - No Resistance and Improved Renal and Bone Profiles with a Single-Table Regimen of D/C/F/TAF
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 22--22
VI  - 14
IP  - 28
4099  - http://mdc.sagepub.com/content/14/28/22.short
4100  - http://mdc.sagepub.com/content/14/28/22.full
AB  - Darunavir is a protease inhibitor (PI) dosed as a single daily tablet. PIs have a high genetic barrier to resistance, but a PI-based single-tablet regimen has not been available. This article presents the results of the week 48 analysis of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-Boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naïve Adults [GS-US-299-0102; NCT01565850].